Synapse - Works

Results (116513)

Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study

Meeting Abstract

Wierda, W. G.; Lewis, D. J.; Ghia, P.; Shah, N. N.; Coombs, C. C.; Cheah, C. Y.; Lamanna, N.; Rhodes, J. M.; Hoffmann, M.; Ma, S.; more...
Blood (2022)

Fulltext@MSK | Save

Efficacy and safety of vodobatinib in patients (pts) with chronic phase Philadelphia positive chronic myeloid leukemia (Ph + CML): A sub group analysis by lines of tyrosine kinase inhibitor (TKI) therapy

Meeting Abstract

Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Rathnam, K.; Khattry, N.; Punatar, S.; Apperley, J. F.; Charbonnier, A.; more...
Blood (2022)

Fulltext@MSK | Save

Pelabresib (CPI-0610) combined with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis: Durability of response and safety beyond week 24

Meeting Abstract

Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Gupta, V.; Palandri, F.; Devos, T.; Rampal, R. K.; Talpaz, M.; Vannucchi, A.; Kuykendall, A.; more...
Blood (2022)

Fulltext@MSK | Save

Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma

Meeting Abstract

Raje, N.; Bahlis, N. J.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M. Y.; Tomasson, M. H.; Damore, M. A.; Jiang, S.; Basu, C.; more...
Blood (2022)

Fulltext@MSK | Save

Preliminary data from the phase I/II study of TP-3654, a selective oral PIM1 kinase inhibitor, in patients with myelofibrosis previously treated with or ineligible for JAK inhibitor therapy

Meeting Abstract

El Chaer, F.; McCloskey, J.; Rein, L. A. M.; Brown, R. A.; Green, S. D.; Pu, J. J.; Shirane, S.; Shimoda, K.; Ichii, M.; Yuda, J.; more...
Blood (2022)

Fulltext@MSK | Save

Outcomes after transplant in relapsed/refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia patients achieving remissions after menin inhibition: SNDX-5613 (revumenib) Ph1 experience

Meeting Abstract

Issa, G. C.; Cuglievan, B.; Stein, E.; Arellano, M. L.; Žucenka, A.; Khera, N.; Stone, R. M.; Thirman, M. J.; DiPersio, J. F.; Karras, N.; more...
Blood (2022)

Fulltext@MSK | Save

Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia

Meeting Abstract

Bewersdorf, J. P.; Patel, K. K.; Goshua, G.; Shallis, R. M.; Podoltsev, N. A.; Stahl, M. F.; Stempel, J. M.; Stein, E.; Huntington, S. F.; Zeidan, A. M.
Blood (2022)

Fulltext@MSK | Save

Efficacy and safety of add-on parsaclisib to ruxolitinib therapy in myelofibrosis patients with suboptimal response to ruxolitinib: Final results from a phase 2 study

Meeting Abstract

Yacoub, A.; Borate, U.; Rampal, R. K.; Ali, H.; Wang, E.; Gerds, A. T.; Hobbs, G. S.; Kremyanskaya, M.; Winton, E.; O'Connell, C.; more...
Blood (2022)

Fulltext@MSK | Save

Imetelstat-mediated alterations in lipid metabolism to induce ferroptosis as therapeutic strategy for acute myeloid leukemia

Meeting Abstract

Bruedigam, C.; Porter, A. H.; Song, A.; in de Wei, G. V.; Stoll, T.; Straube, J.; Cooper, L. T.; Cheng, G. D.; Kahl, V. F. S.; Sobinoff, A.; more...
Blood (2022)

Fulltext@MSK | Save

Variability in pattern of mutational signatures in multiple myeloma as a function of racial origin

Meeting Abstract

Blaney, P.; Boyle, E. M.; Maclachlan, K. H.; Williams, L. S.; Gagler, D.; Sudha, P.; Poos, A. M.; Wang, Y.; Ghamlouch, H.; Tenenbaum, A.; more...
Blood (2022)

Fulltext@MSK | Save